National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease

摘要

Hydroxyurea has benefited some patients with sickle cell disease—an inherited blood disorder that affects 50 000 to 100 000 people in the United States—but several issues about its use are unresolved. To more closely examine this topic, the National Heart, Lung, and Blood Institute and the Office of Medical Applications of Research of the National Institutes of Health convened a Consensus Development Conference to assess the available scientific evidence. This article answers key questions about the evidence.